TY - JOUR
T1 - Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
AU - Cavallari, Ilaria
AU - Delli Veneri, Alessia
AU - Maddaloni, Ernesto
AU - Melfi, Rosetta
AU - Patti, Giuseppe
AU - Napoli, Nicola
AU - Pozzilli, Paolo
AU - Di Sciascio, Germano
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Purpose of the Review: To summarize available evidence regarding lipid-lowering interventions for the prevention of cardiovascular disease in patients with diabetes. Recent Findings: Statins and non-statin therapies that act through upregulation of LDL receptor expression are associated with similar cardiovascular risk reduction per decrease in LDL cholesterol. Summary: In subjects with diabetes, with or without established cardiovascular disease, each 39 mg/dl reduction in LDL cholesterol observed with statins is associated with a 21% relative reduction in the risk of major coronary events at 5 years. Statins remain the first-line lipid-lowering agents for the management of dyslipidemia in individuals with diabetes; however, the addition of non-statin therapies to lower LDL cholesterol, such as ezetimibe and PCSK-9 inhibitors, to maximally tolerated statin therapy is recommended in patients with atherosclerotic cardiovascular disease and baseline LDL cholesterol over 70 mg/dl. Recent data support even lower LDL cholesterol targets (< 55 mg/dl) to further reduce the risk of cardiovascular events especially in subjects with diabetes and documented cardiovascular disease.
AB - Purpose of the Review: To summarize available evidence regarding lipid-lowering interventions for the prevention of cardiovascular disease in patients with diabetes. Recent Findings: Statins and non-statin therapies that act through upregulation of LDL receptor expression are associated with similar cardiovascular risk reduction per decrease in LDL cholesterol. Summary: In subjects with diabetes, with or without established cardiovascular disease, each 39 mg/dl reduction in LDL cholesterol observed with statins is associated with a 21% relative reduction in the risk of major coronary events at 5 years. Statins remain the first-line lipid-lowering agents for the management of dyslipidemia in individuals with diabetes; however, the addition of non-statin therapies to lower LDL cholesterol, such as ezetimibe and PCSK-9 inhibitors, to maximally tolerated statin therapy is recommended in patients with atherosclerotic cardiovascular disease and baseline LDL cholesterol over 70 mg/dl. Recent data support even lower LDL cholesterol targets (< 55 mg/dl) to further reduce the risk of cardiovascular events especially in subjects with diabetes and documented cardiovascular disease.
KW - Cardiovascular disease
KW - Diabetes
KW - Lipid-lowering interventions
UR - http://www.scopus.com/inward/record.url?scp=85055652351&partnerID=8YFLogxK
U2 - 10.1007/s11892-018-1117-y
DO - 10.1007/s11892-018-1117-y
M3 - Review article
SN - 1534-4827
VL - 18
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 12
M1 - 138
ER -
